Robert Hariri, Celularity CEO (Photo by Vivien Killilea/Getty Images for Brain Mapping Foundation)
Celularity ends clinical trial, to now focus on new NK cell therapy amid cash crunch
Celularity is making a brief return to a preclinical-stage company as it closes out a Phase I study of its unmodified natural killer cell therapy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
